Patients with NSCLC harboring activating EGFR mutations benefit from treatment with tyrosine kinase inhibitors (TKIs) as compared to conventional cytotoxic chemotherapy [2]–[4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.